PMID- 38219902
OWN - NLM
STAT- MEDLINE
DCOM- 20240325
LR  - 20240325
IS  - 1535-7732 (Electronic)
IS  - 1051-0443 (Linking)
VI  - 35
IP  - 4
DP  - 2024 Apr
TI  - Safety and Technical Feasibility of Percutaneous Renal Cryoablation of Central 
      Tumors without Pyeloperfusion.
PG  - 533-540
LID - S1051-0443(24)00010-1 [pii]
LID - 10.1016/j.jvir.2024.01.006 [doi]
AB  - PURPOSE: To assess the safety and technical success of percutaneous cryoablation 
      (PCA) without pyeloperfusion in 94 patients with central renal tumors. MATERIALS 
      AND METHODS: A retrospective review of all central renal tumors treated by PCA 
      without pyeloperfusion was performed. Central tumors were defined as those 
      involving the renal sinus fat on preprocedural cross-sectional imaging. Patient 
      demographics and baseline tumor characteristics were recorded. The details of the 
      PCA procedure, primary and secondary technical success, rates of local 
      recurrence, adverse events (AEs), cancer-specific survival (CSS), and overall 
      survival (OS) were compiled. RESULTS: Ninety-four patients (48 females [51%]; 
      mean age, 68.2 years [range, 38-87 years]) with 94 central renal tumors were 
      included. The mean maximal tumor diameter and mean RENAL nephrometry score were 
      37 mm (range, 15-67 mm) and 8 (range, 4-11), respectively. Primary technical 
      success was achieved in 94% (n = 88) of procedures. Of the patients who did not 
      achieve primary technical success, 3 underwent successful repeat PCA (secondary 
      technical success, 97%; n = 91/94). The other 3 patients were surveilled for 
      residual disease. Twenty-four patients (26%) required hydrodissection during PCA. 
      Six patients (6%) experienced major AEs after PCA including hemorrhage requiring 
      embolization (n = 3), hemorrhage requiring transfusions with admission (n = 2), 
      and perinephric abscess necessitating drain placement (n = 1). Twenty-two 
      patients (23%) experienced minor AEs. Nine patients (10%) experienced local 
      recurrence during the follow-up period. OS was 94% (n = 88/94), whereas CSS was 
      98% (n = 92/94) during the study follow-up period (mean, 16 months [range, 1-102 
      months]). CONCLUSIONS: PCA of central renal tumors appears to be safe with high 
      rates of technical success, even without the use of pyeloperfusion.
CI  - Copyright (c) 2024 SIR. Published by Elsevier Inc. All rights reserved.
FAU - Pigg, Richard A
AU  - Pigg RA
AD  - Division of Vascular and Interventional Radiology, University of Alabama at 
      Birmingham, Birmingham, Alabama.
FAU - Raja, Junaid Y
AU  - Raja JY
AD  - Division of Vascular and Interventional Radiology, University of Alabama at 
      Birmingham, Birmingham, Alabama.
FAU - Babar, Tarik
AU  - Babar T
AD  - Division of Vascular and Interventional Radiology, University of Alabama at 
      Birmingham, Birmingham, Alabama.
FAU - Li, Yufeng
AU  - Li Y
AD  - Department of Internal Medicine, University of Alabama at Birmingham, Birmingham, 
      Alabama.
FAU - Li, Mei
AU  - Li M
AD  - Department of Internal Medicine, University of Alabama at Birmingham, Birmingham, 
      Alabama.
FAU - Huang, Junjian
AU  - Huang J
AD  - Division of Vascular and Interventional Radiology, University of Alabama at 
      Birmingham, Birmingham, Alabama.
FAU - Gunn, Andrew J
AU  - Gunn AJ
AD  - Division of Vascular and Interventional Radiology, University of Alabama at 
      Birmingham, Birmingham, Alabama. Electronic address: agunn@uabmc.edu.
LA  - eng
PT  - Journal Article
DEP - 20240112
PL  - United States
TA  - J Vasc Interv Radiol
JT  - Journal of vascular and interventional radiology : JVIR
JID - 9203369
SB  - IM
MH  - Female
MH  - Humans
MH  - Aged
MH  - *Carcinoma, Renal Cell/surgery
MH  - *Cryosurgery/adverse effects/methods
MH  - Feasibility Studies
MH  - Treatment Outcome
MH  - *Kidney Neoplasms/diagnostic imaging/surgery
MH  - Retrospective Studies
MH  - Hemorrhage/etiology
EDAT- 2024/01/15 00:41
MHDA- 2024/03/25 06:44
CRDT- 2024/01/14 19:36
PHST- 2023/06/15 00:00 [received]
PHST- 2023/12/27 00:00 [revised]
PHST- 2024/01/05 00:00 [accepted]
PHST- 2024/03/25 06:44 [medline]
PHST- 2024/01/15 00:41 [pubmed]
PHST- 2024/01/14 19:36 [entrez]
AID - S1051-0443(24)00010-1 [pii]
AID - 10.1016/j.jvir.2024.01.006 [doi]
PST - ppublish
SO  - J Vasc Interv Radiol. 2024 Apr;35(4):533-540. doi: 10.1016/j.jvir.2024.01.006. 
      Epub 2024 Jan 12.